Orlando, Fla.—There are new and pending antibiotics that are broad-spectrum and highly effective, with favorable safety profiles, but that doesn’t mean infectious disease specialists can breathe easy.
“We have new gram-negative antimicrobials in several different areas of importance. However, we are running into a problem: Companies are struggling in the marketplace due to a reluctance to use some of their medications,” said Jason Gallagher, PharmD, a